Diffuse Large B-cell Lymphoma (DLBCL) Clinical Trial
Official title:
Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy
Verified date | May 2024 |
Source | Memorial Sloan Kettering Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the ability of a largely self-administered geriatric assessment (GA) to predict toxicity in non-Hodgkin Lymphoma (NHL) patients ≥60 years old receiving chemotherapy or chemoimmunotherapy.
Status | Active, not recruiting |
Enrollment | 201 |
Est. completion date | April 2025 |
Est. primary completion date | April 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years and older |
Eligibility | Inclusion Criteria: Subjects meeting the following criteria will be eligible for enrollment in the study (unless excluded): - =60 years old - Pathologically confirmed NHL. - Must meet criteria for initiation of treatment; consisting of: - Aggressive histology, or - Indolent histology with one of the following markers of large tumor burden (67): - Any nodal or extranodal tumor mass =7cm in greatest dimension - =3 nodal masses that are each =3 cm in greatest dimension - Systemic symptoms - Cytopenias (leukocytes <1 × 109/L and/or platelets ,100 × 109/L) - Substantial splenomegaly - Serous effusion (plural effusion or peritoneal ascites) - Orbital or epidural involvement - Ureteral compression - Leukemic phase (malignant cells =5 x 109/L) - Must be starting a new chemotherapy regimen (patients whose treatment regimen includes an immunomodulatory agent such as lenalidomide or small molecule targeted agents such as Ibrutinib or Idelelasib will be included in the study; patients being treated with a single agent monoclonal antibody will not be included). - Fluent in English (because not all components of the GA have been validated in other languages) - Able to provide informed consent In addition to the above, subjects meeting the following criteria will be enrolled in the pre-phase arm of the study, until the accrual target for that arm is reached: - Age = 70 years OR KPS = 70 - Pathologically confirmed diagnosis of DLBCL, with or without simultaneous or antecedent indolent lymphoma. - Previously untreated for DLBCL - Intended initial treatment to include =2 cycles of R-CHOP, R-EPOCH or R-CEPP using standard doses and schedule.(68, 69) R-CHOP chemoimmunotherapy may be given every 14 days or every 21 days. (4, 70) Exclusion Criteria: Subjects meeting the following criteria will be excluded from enrollment in the study: - Enrollment in a Phase I trial - Previously enrollment in this study - Patients scoring = 11 on the BOMC (implying cognitive impairment) will be excluded since their ability to reliably complete the questionnaire will be in doubt Subjects meeting the following criteria will be excluded from enrollment in the pre-phase arm of the study, but may be included in the GA only arm. - Contraindication to use of rituximab or prednisone including: - Uncontrolled diabetes mellitus - Systemic fungal infection - Evidence of active hepatitis B infection (i.e. patients testing positive hepatitis B surface antigen or viral DNA by PCR analysis) will be excluded. Patients with evidence of past infection without active viremia (i.e. positive hepatitis B core antibody, negative hepatitis B surface antigen and negative hepatitis B DNA PCR) will be treated with entecavir as per institutional guidelines and may be included in the study. - History of any serious adverse reaction to either a corticosteroid or rituximab not including rituximab infusion reactions = Grade 3. - Patients enrolled on another clinical trial which prohibits the use of pre-phase therapy or any of its components. |
Country | Name | City | State |
---|---|---|---|
United States | Memorial Sloan Kettering Basking Ridge | Basking Ridge | New Jersey |
United States | Memorial Sloan Kettering Commack | Commack | New York |
United States | Memorial Sloan Kettering Westchester | Harrison | New York |
United States | Memorial Sloan Kettering Monmouth | Middletown | New Jersey |
United States | Memorial Sloan Kettering Bergen | Montvale | New Jersey |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Memorial Sloan Kettering Rockville Centre | Rockville Centre | New York |
United States | Memorial Sloan Kettering Nassau | Uniondale | New York |
Lead Sponsor | Collaborator |
---|---|
Memorial Sloan Kettering Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Toxicity Assessment | Hospitalization during or within 30 days following chemotherapy Dose delay or reduction to a dose intensity =80% of the planned dose intensity. Dose reductions occurring prior to cycle 1 of chemotherapy will be counted as events. Discontinuation of chemotherapy due to toxicity Grade 3 or higher non-hematologic toxicity Grade 4 or higher hematologic toxicity. Using the NCI CTCAE v4.0 toxicity grading | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06043011 -
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
|
||
Not yet recruiting |
NCT05532761 -
Multidimensional Assessment of Quality of Life, Social and Professional Life and Care Utilization in Patients With Diffuse Large Cell B-cell Lymphoma Treated With CAR-T Cells
|
||
Not yet recruiting |
NCT05596097 -
Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission
|
Phase 2 | |
Terminated |
NCT02914938 -
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
|
Phase 1 | |
Active, not recruiting |
NCT02570542 -
Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
|
Phase 2 | |
Terminated |
NCT00482053 -
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
|
Phase 2 | |
Active, not recruiting |
NCT04049513 -
ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)
|
Phase 1 | |
Recruiting |
NCT05364424 -
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
|
Phase 1 | |
Terminated |
NCT02983097 -
Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP
|
Phase 1/Phase 2 | |
Completed |
NCT00001337 -
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT04830137 -
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
|
Phase 1 | |
Recruiting |
NCT03547115 -
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
|
Phase 1 | |
Completed |
NCT04933617 -
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
|
Phase 1 | |
Not yet recruiting |
NCT04767308 -
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
|
Early Phase 1 | |
Recruiting |
NCT04836507 -
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583149 -
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
|
Phase 2 | |
Terminated |
NCT02957019 -
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
|
Phase 1/Phase 2 | |
Completed |
NCT02445248 -
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
|
Phase 2 | |
Withdrawn |
NCT04456023 -
Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)
|
Phase 2 | |
Recruiting |
NCT06256484 -
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
|
Phase 1 |